What are the evidence‑based treatment options for binge eating disorder, including psychotherapy and pharmacologic therapies?

Binge Eating Disorder Treatment

Start with eating disorder-focused cognitive-behavioral therapy (CBT) or interpersonal therapy (IPT) as first-line treatment for binge eating disorder, delivered in either individual or group formats. 1

First-Line Treatment: Psychotherapy

The American Psychiatric Association provides a strong recommendation (1C) that psychotherapy should be the initial treatment approach for binge eating disorder. 1

Specific Psychotherapy Options:

• Cognitive-behavioral therapy (CBT): This is the most robustly supported intervention, with large effect sizes for reducing binge eating episodes and related psychopathology. 1, 2, 3, 4 CBT demonstrates moderate quality evidence and should target eating patterns, cognitive distortions about food and body image, and behavioral patterns maintaining the disorder. 2, 3

• Interpersonal therapy (IPT): This is an equally valid first-line option, focusing on interpersonal relationships and emotional triggers for binge eating. 1, 2 IPT has modest support with low quality evidence but remains a recommended alternative. 2

• Delivery format: Both individual and group formats are effective, allowing flexibility based on patient preference and resource availability. 1

Emerging Psychotherapy Approaches:

• Guided self-help CBT: This has moderate quality evidence supporting its efficacy and offers a more accessible, cost-effective option. 2, 3, 4

• Integrative cognitive therapy and emotion regulation skills training: Recent evidence (2018-2022) confirms efficacy for binge eating and associated psychopathology, though with lower effect sizes than traditional CBT. 5

Second-Line Treatment: Pharmacotherapy

If the patient prefers medication or shows minimal/no response to psychotherapy alone by 6 weeks, add pharmacologic treatment. 1

Medication Options (in order of evidence strength):

1. Lisdexamfetamine: This has the strongest pharmacologic evidence with low quality support. 1, 2, 3

   • Reduces binge eating frequency significantly (RR 2.61,95% CI 2.04-3.33). 3
   • Provides modest weight loss (MD -4.6 to -6.5 kg). 3, 6
   • Reduces binge-eating-related obsessions and compulsions (MD -6.50). 3
   • Common side effects: Headache, gastrointestinal upset, sleep disturbance, sympathetic nervous system arousal (RR 1.63-4.28 compared to placebo), and dry mouth. 3, 6

2. Antidepressants (SSRIs/SGAs): These have modest support with low quality evidence. 1, 2, 3

   • Increase binge-eating abstinence (RR 1.67,95% CI 1.24-2.26). 3
   • Reduce binge-eating-related obsessions/compulsions (MD -3.84) and depression symptoms (MD -1.97). 3
   • Do not produce significant weight loss. 3, 4

3. Topiramate: While not mentioned in APA guidelines, recent network meta-analysis shows comparable efficacy to lisdexamfetamine. 6

   • Reduces binge frequency (MD -1.63,95% CI -2.53 to -0.74). 6
   • Produces greatest weight loss among medications (MD -5.5 kg). 3, 6
   • Associated with sympathetic nervous system arousal. 3

4. Naltrexone/bupropion: This combination showed modest weight effects but lacks clear efficacy for binge reduction (MD -2.07,95% CI -4.45 to 0.31) and should not be prioritized. 6

Treatment Algorithm:

1. Initiate eating disorder-focused CBT or IPT (individual or group format). 1

2. Assess response at 6 weeks: 1

   • If good response: Continue psychotherapy
   • If minimal/no response OR patient preference for medication: Add pharmacotherapy

3. Pharmacotherapy selection: 1, 3, 6

   • First choice: Lisdexamfetamine (if weight loss desired and no contraindications)
   • Alternative: Topiramate (if greater weight loss needed)
   • Alternative: SSRI/SGA (if comorbid depression or anxiety)

4. Combination therapy: Adding medication to psychotherapy does not consistently augment efficacy beyond single treatments, but may be considered for treatment-refractory cases. 5, 4

Critical Caveats:

• Weight loss expectations: Most treatments show disappointing results for weight reduction except lisdexamfetamine and topiramate, which produce only modest effects. 2, 3, 6 Behavioral weight loss treatment shows efficacy for both binge eating and weight loss. 5

• Long-term data: There is limited support for long-term effects of psychological treatments and no data on long-term effects of medications, which is particularly concerning for pharmacotherapy. 2 This should inform shared decision-making about medication use.

• Treatment resistance: Approximately 20-30% of patients fail to respond to best available treatments and develop persistent treatment-refractory illness. 7 These patients may require novel approaches or stepped-care models. 5

• Multidisciplinary approach: Treatment plans should incorporate medical, psychiatric, psychological, and nutritional expertise, ideally through a coordinated team. 1

Essential Initial Assessment:

Before initiating treatment, document: 1

• Binge eating frequency, intensity, and patterns
• Weight history and current BMI
• Co-occurring psychiatric disorders (depression, anxiety)
• Comprehensive metabolic panel, CBC, liver/renal function
• Vital signs including orthostatic measurements
• Prior treatment responses